Skip to content
Lucid News· Jack Gorsline·AI score62

Policy briefing rounds up MDMA application resubmission, LSD phase 3 results and Canadian cannabis consortium

Psychedelic Policy Briefing 8.21.26

AI summary

A policy briefing reports that Resilient Pharmaceuticals, formerly Lykos Therapeutics and MAPS PBC.

Key facts

Kind of item
Trial results
Compound
LSD
Condition
Anxiety
Jurisdiction
United States
Trial phase
Phase 3
Source
Lucid News (lucid.news)
Published
How this summary was made

The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: Lucid News · lucid.news

Connected to

Kind of item
Trial results
Compound
LSD
Condition
Anxiety
Jurisdiction
United States

Other recent items on these topics